science wire

A language app to improve diagnosis and peer-support dementia coaching are some of the Sydney projects aiming to tackle the obstacles and stigma surrounding dementia.

First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici

Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infecti

New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1

There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with sta

Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA).

Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS) ; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 pos

Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started OCREVUS after the double-blind period Interim analysis of Phase IIIb study shows 87 percent of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to OCREVUS Separ

New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, inc

The University of Birmingham will play a key role in new data hubs that will enable cutting-edge research for health discoveries and aim to give patients across the UK faster access to pioneering new treatments. Led by Health Data Research UK , the hubs aim to improve the lives of people with debilitating conditions, and will link up different types of health data and make it more easily accessible and user-friendly for research, while maintaining strict controls around data privacy and consent.

By Pelzl New simulation technology developed by TU Graz is designed to make the production of biopharmaceuticals more efficient, cost-effective and comprehensible for manufacturers.

Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 2019 74% reduction in the risk of relapse for s

Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) Roche today announced positive data from the Phase III IM

Ventrix, a University of California San Diego spin-off company, has successfully conducted a first-in-human, FDA-approved Phase 1 clinical trial of an injectable hydrogel that aims to repair damage and restore cardiac function in heart failure patients who previously suffered a heart attack. The trial is the first to test a hydrogel designed to repair cardiac tissue.

The U.S. Food and Drug Administration has  approved  a new antibiotic that, in combination with two existing antibiotics, can tackle one of the most formidable and deadly treatment-resistant forms of the bacterium that causes tuberculosis .

Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future disability outcomes Separate analyses presented from one of the first studies to demonstrate NfL levels are correlated with active MRI lesions in PPMS Roche today announced new data from OCREVUS (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS).

The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years

A study led by the University of Birmingham provides strong support for current recommendations on treating patients with an underactive thyroid and validates latest UK and US guidelines, say researchers. The retrospective cohort study , published in The BMJ , analysed anonymous GP records of over 162,000 patients who have been diagnosed with hypothyroidism - a highly prevalent condition more commonly known as an underactive thyroid.

Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stag

Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neuro

An extreme case of "fussy" or "picky" eating caused a young patient's blindness, according to a new case report published today [2 Sep 2019] in Annals of Internal Medicine.

Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients ; EVALUATE-HF results complement findings   PROVE-HF establishes significant correlation between improvement in widely used cardiac biomarker and positive changes in heart structure and ability to pump blood in patients taking Entresto   Safety and tole

BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an

Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose

Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.

The number of patients with heart failure with preserved ejection fraction is on the rise, and the search is on for a therapy that can improve health outcomes in this group of patients for whom no approved therapies are available.

In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio * (teriflunomide) in patients with relapsing forms of MS (RMS) Key secondary endpoi

This Friday, 30 August, a team of EPFL students will take part in the SensUs competition at the Eindhoven University of Technology.

The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer - an aggressive and difficult-to-treat disease Approval based on the

This launch represents an important step in Roche's personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine Each year 300,000 patients around the

A new rapid patient test which could identify whether bacteria isolated from clinical samples are antibiotic resistant in under two hours is being trialled on a range of antibiotics commonly used to treat urinary tract infections (UTIs).

PARAGON-HF trial will provide Entresto (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF)   New PROVE-HF and EVALUATE-HF studies will highlight Entresto's direct impact on the heart in heart failure with reduced ejection fraction (HFrEF)   New PIONEER-HF and TRANSITION-HF findings will advance understanding of Entresto use in patients hospitalized for decompensated HFrEF following stabilizatio

Sal Levinson: I'm Sal Levinson - I'm a propagator at the UC Botanical Garden. I work in native propagation, I grow plants that we sell here, and I also do the butterfly tours here.

First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?

First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?

Basel, August 6, 2019 - Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma. The FDA supports the continued marketing and use of Zolgensma for patients with spinal muscular atrophy (SMA) less than 2 years of age.

IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including